Glioblastoma patients in Slovenia from 1997 to 2008

1. Hoffman S, Propp JM, McCarthy BJ. Temporal trends in incidence of primary brain tumors in the United States, 1985-1999. Neuro Oncol 2006; 8: 27-37.10.1215/S1522851705000323Search in Google Scholar

2. Schneider T, Mawrin C, Scherlach C, Skalej M, Firsching R. Gliomas in adults. Dtsch Arztebl Int 2010; 107: 799-807.10.3238/arztebl.2010.0799Search in Google Scholar

3. Kachanov DY, Dobrenkov KV, Shamanskaya TV, Abdullaev RT, Inushkina EV, Varfolomeeva SR, et al. Solid tumors in young children in Moscow Region of Russian Federation. Radiol Oncol 2008; 42: 39-44.10.2478/v10019-007-0037-2Search in Google Scholar

4. Chojnacka M, Skowronska-Gardas A, Pedziwiatr K, Morawska-Kaczynska M, Perek M, Perek D. Reirradiation of relapsed brain tumors in children. Rep Pract Oncol Radiother 2012; 17: 32-7.10.1016/j.rpor.2011.10.004Search in Google Scholar

5. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO classfication of tumours of the central nervous system. Lyon: IARC; 2007.10.1007/s00401-007-0278-6Search in Google Scholar

6. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol 2005; 109: 93-108.10.1007/s00401-005-0991-ySearch in Google Scholar

7. Ohgaki H. Epidemiology of brain tumors. Methods Mol Biol 2009; 472: 323-42.10.1007/978-1-60327-492-0_14Search in Google Scholar

8. Chakrabarti I, Cockburn M, Cozen W, Wang YP, Preston-Martin S. A population- based description of glioblastoma multiforme in Los Angeles County, 1974-1999. Cancer 2005; 104: 2798-806.10.1002/cncr.21539Search in Google Scholar

9. Tezcan Y, Koc M. 3-D conformal radiotherapy with concomitant and adjuvant temozolomide for patients with glioblastoma multiforme and evaluation of prognostic factors. Radiol Oncol 2011; 45: 213-9.10.2478/v10019-011-0019-2Search in Google Scholar

10. Cancer in Slovenia 2008. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia; 2011.Search in Google Scholar

11. Catt S, Chalmers A, Fallowfield L. Psychosocial and supportive-care needs in high-grade glioma. Lancet Oncol 2008; 9: 884-91.10.1016/S1470-2045(08)70230-4Search in Google Scholar

12. Baur M, Preusser M, Piribauer M, Elandt K, Hassler M, Hudec M, et al. Frequent MGMT (06-methylguanine-DNA methyltransferase) hypermethylation in long-term survivors of glioblastoma: a single institution experience. Radiol Oncol 2010; 44: 113-120.10.2478/v10019-010-0023-y342368822933901Search in Google Scholar

13. Zada G, Bond AE, Wang YP, Giannotta SL, Deapen D. Incidence trends in the anatomic location of primary malignant brain tumors in the United States: 1992-2006. World Neurosurg 2012; 77: 518-24.10.1016/j.wneu.2011.05.05122120376Search in Google Scholar

14. Cancer in Slovenia 2008. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia; 2011.Search in Google Scholar

15. Niemiec M, Glogowski M, Tyc-Szczepaniak D, Wierzchowski M, Kepka L. Characteristics of long-term survivors of brain metastases from lung cancer. Rep Pract Oncol Radiother 2011; 16: 49-53.10.1016/j.rpor.2011.01.002386316524376956Search in Google Scholar

16. Strojan P. Role of radiotherapy in melanoma management. Radiol Oncol 2010: 44: 1-12.10.2478/v10019-010-0008-x342366822933884Search in Google Scholar

17. Nieder C, Astner ST, Mehta MP, Grosu AL, Molls M. Improvement, clinical course, and quality of life after palliative radiotherapy for recurrent glioblastoma. Am J Clin Oncol 2008; 31: 300-5.10.1097/COC.0b013e31815e3fdc18525311Search in Google Scholar

18. Ziobro M, Rolski J, Grela-Wojewoda A, Zygulska A, Niemiec M. Effects of palliative treatment with temozolomide in patients with high-grade gliomas. Neurol Neurochir Pol 2008; 42: 210-5.Search in Google Scholar

19. Dresemann G. Temozolomide in malignant glioma. Onco Targets Ther 2010; 3: 139-46.10.2147/OTT.S5480Search in Google Scholar

20. Niyazi M, Schwarz SB, Suchorska B, Belka C. Radiotherapy with and without temozolomide in elderly patients with glioblastoma. Strahlenther Onkol 2012; 188: 154-9.10.1007/s00066-011-0026-722231634Search in Google Scholar

21. Scott JG, Suh JH, Elson P, Barnett GH, Vogelbaum MA, Peereboom DM, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or older: a retrospective review of 206 cases. Neuro Oncol 2011; 13: 428-36.10.1093/neuonc/nor005306469921363881Search in Google Scholar

22. Ramakrishna R, Kim L, Rostomily R. Glioblastoma: the importance of not being ageist. World Neurosurg 2011; 76: 369-70.10.1016/j.wneu.2011.08.02822152553Search in Google Scholar

23. Ohgaki H. Genetic pathways to glioblastomas. Neuropathology 2005; 25: 1-7.10.1111/j.1440-1789.2004.00600.x15822813Search in Google Scholar

24. Purow BW, Schiff D. Glioblastoma genetics: in rapid flux. Discov Med 2010; 9(45): 125-31.Search in Google Scholar

25. Onishi M, Ichikawa T, Kurozumi K, Date I. Angiogenesis and invasion in glioma. Brain Tumor Pathol 2011; 28: 13-24.10.1007/s10014-010-0007-z21221826Search in Google Scholar

26. Siebzehnrubl FA, Reynolds BA, Vescovi A, Steindler DA, Deleyrolle LP. The origins of glioma: E Pluribus Unum? Glia 2011; 59: 1135-47.Search in Google Scholar

27. Brennan C. Genomic profiles of glioma. Curr Neurol Neurosci Rep 2011; 11: 291-7.10.1007/s11910-011-0198-721465149Search in Google Scholar

28. Sulman EP, Guerrero M, Aldape K. Beyond grade: molecular pathology of malignant gliomas. Semin Radiat Oncol 2009; 19: 142-9.10.1016/j.semradonc.2009.02.00119464628Search in Google Scholar

29. Connelly JM, Malkin MG. Environmental risk factors for brain tumors. Curr Neurol Neurosci Rep 2007; 7: 208-14.10.1007/s11910-007-0032-417488586Search in Google Scholar

30. Ng K, Kim R, Kesari S, Carter B, Chen CC. Genomic profiling of glioblastoma: convergence of fundamental biologic tenets and novel insights. J Neurooncol 2012; 107: 1-12.10.1007/s11060-011-0714-222002595Search in Google Scholar

31. Hentschel SJ, Lang FF. Current surgical management of glioblastoma. Cancer J 2003; 9: 113-25.10.1097/00130404-200303000-0000712784877Search in Google Scholar

32. Oszvald A, Güresir E, Setzer M, Vatter H, Senft C, Seifert V, et al. Glioblastoma therapy in the elderly and the importance of the extent of resection regardless of age. J Neurosurg 2012; 116: 357-64.10.3171/2011.8.JNS10211421942727Search in Google Scholar

33. Vranic A. New developments in surgery of malignant Gliomas. Radiol Oncol 2011; 45: 159-65.10.2478/v10019-011-0018-3342373622933950Search in Google Scholar

34. Stupp R, Mason WP, Van Den Bent MJ, Weller M. Fisher B, Taphoorn M, et al. Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group. [Abstract]. J Clin Oncol 2004; 22(14 Suppl): 1S.10.1200/jco.2004.22.90140.2Search in Google Scholar

35. Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC, et al; ALA-Glioma Study Group. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 2008; 62: 564-76.10.1227/01.neu.0000317304.31579.1718425006Search in Google Scholar

36. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001; 95: 190-8.10.3171/jns.2001.95.2.0190Search in Google Scholar

37. Laperriere N, Zuraw L, Cairncross G; Cancer Care Ontario Practice Guidelines Initiative Neuro-Oncology Disease Site Group. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol 2002; 64: 259-73.10.1016/S0167-8140(02)00078-6Search in Google Scholar

38. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.10.1056/NEJMoa043330Search in Google Scholar

39. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-66.10.1016/S1470-2045(09)70025-7Search in Google Scholar

40. Bondiau PY, Fauchon F, Jadaud E, Paquis P. Radiothérapie des glioblastomes de l’adulte Neurochirurgie 2010; 56: 486-90.Search in Google Scholar

41. Gerstein J, Franz K, Steinbach JP, Seifert V, Rödel C, Weiss C. Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-term outcome of unselected patients from a single institution. Strahlenther Onkol 2011; 187: 722-8.10.1007/s00066-011-2230-x22037649Search in Google Scholar

42. Burton EC, Prados MD. Malignant gliomas. Curr Treat Options Oncol 2000; 1: 459-68.10.1007/s11864-000-0073-212057153Search in Google Scholar

43. Mangiola A, Anile C, Pompucci A, Capone G, Rigante L, De Bonis P. Glioblastoma therapy: going beyond Hercules Columns. Expert Rev Neurother 2010; 10: 507-14.10.1586/ern.09.15820367204Search in Google Scholar

44. Brandes AA, Tosoni A, Franceschi E, Reni M, Gatta G, Vecht C. Glioblastoma in adults. Crit Rev Oncol Hematol 2008; 67: 139-52.10.1016/j.critrevonc.2008.02.00518394916Search in Google Scholar

45. Trinh VA, Patel SP, Hwu WJ. The safety of temozolomide in the treatment of malignancies. Expert Opin Drug Saf 2009; 8: 493-9.10.1517/1474033090291828119435405Search in Google Scholar

46. McDonald MW, Shu HK, Curran WJ Jr, Crocker IR. Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma. Int J Radiat Oncol Biol Phys 2011; 79: 130-6.10.1016/j.ijrobp.2009.10.04820399036Search in Google Scholar

47. Gerstein J, Franz K, Steinbach JP, Seifert V, Fraunholz I, Weiss C, et al. Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma. Radiother Oncol 2010; 97: 382-6.10.1016/j.radonc.2010.06.01420850883Search in Google Scholar

48. van Genugten JA, Leffers P, Baumert BG, Tjon-A-Fat H, Twijnstra A. Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice. J Neurooncol 2010; 96: 249-57.10.1007/s11060-009-9956-7280853619582373Search in Google Scholar

49. Johnson DR, O’Neill BP. Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol 2012; 107: 359-64.10.1007/s11060-011-0749-422045118Search in Google Scholar

50. Smrdel U. Salvage therapy after failure of first line treatment for glioblastoma multiforme. [Abstract]. J Neurooncol 2010; 12(Suppl 3): 44-5.Search in Google Scholar

51. Niewald M, Berdel C, Fleckenstein J, Licht N, Ketter R, Rübe C. Toxicity after radiochemotherapy for glioblastoma using temozolomide--a retrospective evaluation. Radiat Oncol 2011; 6: 141.10.1186/1748-717X-6-141321307122017800Search in Google Scholar

52. Niyazi M, Schwarz SB, Suchorska B, Belka C. Radiotherapy with and without temozolomide in elderly patients with glioblastoma. Strahlenther Onkol 2012; 188: 154-9.10.1007/s00066-011-0026-722231634Search in Google Scholar

53. VelnarT, Smrde U, Popovic M, Bunc G. Genetic markers in oligodendroglial tumours. Radiol Oncol 2010; 44: 13-8.Search in Google Scholar

54. Ardebili SY, Zajc I, Gole B, Campos B, Herold-Mende C, Drmota S, et al. CD133/prominin1 is prognostic for GBM patient’s survival, but inversely correlated with cysteine cathepsins’ expression in glioblastoma derived spheroids. Radiol Oncol 2011; 45: 102-15.10.2478/v10019-011-0015-6342373122933943Search in Google Scholar

55. Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Arch Neurol 2008; 65: 877-83.10.1001/archneur.65.7.87718625854Search in Google Scholar

56. Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009; 27: 5743-50.10.1200/JCO.2009.23.080519805672Search in Google Scholar

57. Narayana A, Gruber D, Kunnakkat S, Golfinos JG, Parker E, Raza S, et al. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J Neurosurg 2012; 116: 341-5.10.3171/2011.9.JNS1165622035272Search in Google Scholar

58. Gilbert MR, Kuhn J, Lamborn KR, Lieberman F, Wen PY, Mehta M, et al. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neurooncol 2012; 106: 147-53. 10.1007/s11060-011-0650-1435186921739168Search in Google Scholar